Advertisement
ABBV vs NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Both ABBV and NVS are large-cap pharmaceutical leaders navigating patent cliffs, but their growth engines differ sharply in composition.
- AbbVie's relative performance is anchored by fast-growing immunology drugs Skyrizi and Rinvoq, which together offset a steep decline in legacy blockbuster Humira.
- Novartis is powered by strong oncology and neuroscience momentum (Kisqali, Kesimpta, Pluvicto, Scemblix), even as generic competition pressures Entresto.
- AbbVie offers a "Dividend King" income profile with decades of payout growth, while Novartis emphasizes share buybacks and pipeline-driven expansion.
- Recent market activity has favored Novartis on a momentum basis, but its 2026 outlook reflects a heavier near-term generic headwind.
- Sentiment differs: AbbVie pulled back after strong earnings that missed loftier expectations, while Novartis has drawn both upgrades and caution around its patent cliff.
Introduction
Investors evaluating large-cap healthcare exposure frequently weigh ABBV and NVS as two of the sector's most prominent diversified pharmaceutical franchises. Both companies generate tens of billions in annual revenue, maintain deep R&D (research and development) pipelines, and face the same structural challenge: protecting growth as older blockbusters lose exclusivity. This stock comparison is particularly relevant for long-term, dividend-oriented investors seeking defensive positioning, as well as traders tracking relative performance and momentum shifts. By examining each company's recent results, growth drivers, and market positioning side by side, this article aims to clarify the trade-offs between two superficially similar but strategically distinct pharmaceutical giants.
ABBV Overview and Recent Performance
AbbVie (ABBV) is a U.S.-based biopharmaceutical company with leading franchises in immunology, oncology, neuroscience, and aesthetics. Its recent market behavior has been defined by a resilient core offsetting a known patent cliff. In its most recent quarterly results, revenue rose roughly 9% year over year, driven by immunology leaders Skyrizi (up about 46%) and Rinvoq (up about 34%), while neuroscience sales also expanded at a double-digit pace. This growth has largely absorbed the ongoing erosion of Humira, which lost U.S. exclusivity in 2023 and has since fallen below $1 billion in quarterly sales.
Sentiment, however, has been mixed. Despite beating revenue and adjusted EPS (earnings per share) expectations, shares dipped after the report as investors weighed a sharp drop in reported operating margin, higher acquired R&D charges, and continued softness in the aesthetics segment amid weaker consumer discretionary spending. AbbVie raised its full-year adjusted EPS guidance and increased its quarterly dividend, reinforcing its status as a Dividend King with decades of consecutive payout growth. The company has also expanded its pipeline through targeted acquisitions, including in vivo CAR-T and neuroscience platforms, positioning itself for growth into the next decade.
NVS Overview and Recent Performance
Novartis (NVS) is a Swiss pharmaceutical company that, following its 2023 Sandoz spin-off, focuses on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. Recent quarters have showcased a "changing of the guard," with next-generation drugs driving growth while legacy products face generics. Oncology has been the standout, with Kisqali (up about 68%), Kesimpta (up about 44%), Pluvicto (up about 45%), and Scemblix (nearly doubling) all posting strong momentum.
These gains have offset a generic-driven decline in Entresto, the company's top-selling heart-failure drug, which began losing U.S. exclusivity in 2025. Novartis shares delivered a notably strong year-to-date advance, though the stock pulled back after results that slightly missed earnings expectations and revealed slowing core operating profit growth. Management reaffirmed high-single-digit sales growth guidance but signaled a more conservative 2026, reflecting a heavier patent-cliff burden. Strategic acquisitions, including a roughly $12 billion deal for Avidity Biosciences, underscore a push to strengthen the neuroscience pipeline, while substantial buybacks highlight a commitment to returning capital to shareholders.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's most capable algorithmic trading systems. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and basket of securities. Because market conditions constantly shift, only the bots best suited to the current environment earn a place in this curated section. The featured robots span a wide range of approaches, from short-term swing trading to longer-horizon trend-following, giving investors flexibility in how they apply AI-driven signals to names like ABBV and NVS. Explore the Trending AI Robots page to review the latest top-performing strategies.
Head-to-Head Comparison
The clearest contrast between ABBV and NVS lies in how each manages its patent-cliff transition. AbbVie's growth is concentrated in immunology, where Skyrizi and Rinvoq carry durable patent protection (with Rinvoq's U.S. biosimilar exposure deferred into the 2030s), while its oncology and aesthetics segments remain softer. Novartis, by contrast, leans on a broader mix of oncology and neuroscience blockbusters, but its near-term guidance is clouded by a steeper generic wall across Entresto, Tasigna, and Promacta.
From a shareholder-return perspective, AbbVie emphasizes a rising dividend, appealing to income-focused investors, whereas Novartis prioritizes large-scale buybacks alongside a growing dividend. On valuation and momentum, Novartis has shown stronger recent price appreciation, yet its forward outlook implies a near-term earnings plateau, while AbbVie trades at a comparatively modest forward multiple with a more visible, if steadier, growth path. Risk profiles also diverge: AbbVie faces consumer-driven weakness in aesthetics and margin pressure from elevated R&D spend, while Novartis contends with litigation and regulatory uncertainty tied to Entresto and Medicare price-negotiation dynamics.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely lean toward ABBV for its steadier trend structure and defensive income profile, supported by visible immunology growth and a predictable dividend. However, the AI would also recognize NVS as a higher-momentum, higher-beta alternative, given its strong oncology execution and pipeline catalysts. The probable signal favors AbbVie on stability and risk-adjusted positioning in the current environment, while acknowledging that a cleaner resolution of Novartis's generic headwinds could shift the relative ranking. As with all probabilistic models, these signals reflect current conditions and may change as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and NVS is a Hold.
ABBV in upward trend: price rose above 50-day moving average on September 10, 2026
ABBV moved above its 50-day moving average on September 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 55 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 31 of 47 cases over the following month. The odds of a continued upward trend are 66%.
Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 220 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 233 of 360 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.199). ABBV has a moderately high P/E Ratio (75.220) as compared to the industry average of (34.793). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.026) settles around the average of (0.025) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
NVS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVS's RSI Indicator exited the oversold zone, 15 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 37 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.720) is normal, around the industry mean (19.199). P/E Ratio (22.187) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). Dividend Yield (0.032) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
ABBV | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 48 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 2 | 7 | |
SMR RATING 1..100 | 1 | 33 | |
PRICE GROWTH RATING 1..100 | 11 | 45 | |
P/E GROWTH RATING 1..100 | 76 | 21 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as ABBV (16). This means that NVS’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (7). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (33). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's Price Growth Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (45). This means that ABBV’s stock grew somewhat faster than NVS’s over the last 12 months.
NVS's P/E Growth Rating (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (76). This means that NVS’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 29% | 5 days ago 63% |
| Stochastic ODDS (%) | 3 days ago 44% | 3 days ago 41% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 46% |
| MACD ODDS (%) | 3 days ago 66% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 51% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 54% |
| Declines ODDS (%) | 18 days ago 46% | 13 days ago 45% |
| BollingerBands ODDS (%) | 3 days ago 38% | 3 days ago 32% |
| Aroon ODDS (%) | 3 days ago 65% | 3 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 4 bearish.
- NVS’s TA Score: 6 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +3.87% price change this week, while NVS (@Pharmaceuticals: Major) price change was +4.78% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.91%. For the same industry, the average monthly price growth was -4.47%, and the average quarterly price growth was +3.55%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 30, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.91% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.71% | ||
| NVS - ABBV | 50% Loosely correlated | +0.16% | ||
| JNJ - ABBV | 49% Loosely correlated | +0.90% | ||
| AMGN - ABBV | 48% Loosely correlated | -0.35% | ||
| BMY - ABBV | 47% Loosely correlated | -1.35% | ||
| BIIB - ABBV | 41% Loosely correlated | -1.15% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.